Results 151 to 160 of about 1,268 (176)

Efgartigimod-alfa

Reactions Weekly, 2023
openaire   +1 more source

Efgartigimod Alfa Injection (Vyvgart SC)

Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Vyvgart SC be reimbursed by public drug plans as monotherapy for adult patients with active chronic inflammatory demyelinating polyneuropathy (CIDP), if certain conditions are met. Vyvgart SC should only be covered for adults with CIDP confirmed by electrodiagnostic testing, or for adults with possible ...
openaire   +1 more source

Efgartigimod improves triple-negative myasthenia gravis

Neurological Sciences, 2023
Rita Frangiamore, Elena Rinaldi, Fiammetta Vanoli, Francesca Andreetta, Renato Mantegazza, Carlo Antozzi   +5 more
openaire   +2 more sources

Efgartigimod successful in immune thrombocytopenia 

Medicom Conference Report ASH 2022, 2023
openaire   +1 more source

Study of efgartigimod as a new treatment for pemphigus

British Journal of Dermatology, 2022
openaire   +1 more source

Efgartigimod-alfa/prednisone

Reactions Weekly
openaire   +1 more source

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)

Neurotherapeutics
Sophie Steeland, Benjamin Van Hoorick, Jana Podhorna   +2 more
exaly  

Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events

Muscle and Nerve
Madeline L Singer, Sami Khella, S J Bird   +2 more
exaly  

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases

Expert Review of Clinical Immunology
Adrian C Newland, Yoshitaka Miyakawa, Peter Ulrichts   +2 more
exaly  

Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases

Frontiers in Immunology
Ruixia Zhu, Zhu Ruixia
exaly